Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world safety and effectiveness of Thiopenafigrastine for prevention of chemotherapy-related neutropenia in breast cancer
ChiCTR2500102044Phase 4Not yet recruiting
- Sponsor
- Affiliated Hospital of Qinghai University
- Start
- May 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mecapegfilgrastim in breast cancer and neutropenia, sponsored by Affiliated Hospital of Qinghai University. Primary endpoint: Safety. Planned start May 2025; status: not yet recruiting.
02
Drugs
mecapegfilgrastim
03
Conditions
breast cancerneutropenia
Beyond the preview
Go deeper on ChiCTR2500102044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102044.